newsfilter
← Latest News
Business Wire·

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Alkermes plc (NASDAQ:ALKS) today announced that alixorexton, a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2